TCGA-A7-A4SF-01A-11R-A266-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 18
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.440
- E2F_TARGETS+0.420
- DNA_REPAIR+0.350
- G2M_CHECKPOINT+0.310
- PEROXISOME+0.300
- FATTY_ACID_METABOLISM+0.240
- OXIDATIVE_PHOSPHORYLATION+0.220
- BILE_ACID_METABOLISM+0.160
- MYC_TARGETS_V1+0.150
- GLYCOLYSIS+0.140
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- TNFA_SIGNALING_VIA_NFKB-0.450
- KRAS_SIGNALING_UP-0.400
- INFLAMMATORY_RESPONSE-0.390
- HEDGEHOG_SIGNALING-0.380
- TGF_BETA_SIGNALING-0.340
- UV_RESPONSE_DN-0.340
- PANCREAS_BETA_CELLS-0.330
- ALLOGRAFT_REJECTION-0.300
- IL6_JAK_STAT3_SIGNALING-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R115 | — | — | 0.889 |
| 2 | TCGA-CN-A6V7-01A-12R-A34R-07 | — | — | 0.887 |
| 3 | SRR6013549 | — | cohortSQ2 | 0.886 |
| 4 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.882 |
| 5 | 513fb61a-1339-45d2-8963-6337e3aff5df | — | — | 0.879 |
| 6 | TCGA-BH-A0HU-01A-11R-A034-07 | — | B | 0.879 |
| 7 | TCGA-A8-A079-01A-21R-A00Z-07 | — | B | 0.878 |
| 8 | SRR26320088 | — | — | 0.874 |
| 9 | TCGA-B6-A0X5-01A-21R-A109-07 | — | B | 0.874 |
| 10 | 64935b9c-623d-40d4-bd89-f2af006b1f92 | — | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.310 | Inavolisib | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.140 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.050 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |